Effect and Safety of Compound Glycyrrhizin Combined with Entecavir in the Treatment of Patients with Hepatitis B Cirrhosis
Objective:To investigate the effect and safety of Compound Glycyrrhizin combined with Entecavir in the treatment of patients with hepatitis B cirrhosis.Method:A total of 122 patients with hepatitis B cirrhosis who treated in the Third People's Hospital of Gansu Province from March 2020 to February 2023 were selected as the research objects,the patients were divided into the reference group(Entecavir)and the combined group(Compound Glycyrrhizin combined with Entecavir)according to the random number table method,61 cases in each group.The clinical efficacy,liver fibrosis indexes,liver function indexes,liver hardness,coagulation function and incidence of adverse reactions during treatment were compared between two groups.Result:The total clinical effective rate of the combined group was 95.08%(58/61),which was significantly higher than 80.33%(49/61)of the reference group,and the difference was statistically significant(P<0.05).After treatment,the hyaluronic acid(HA),type Ⅳ collagen(Ⅳ-C),type Ⅲ procollagen(PC-Ⅲ)and laminin(LN)in two groups were lower than those before treatment,and those in the combined group were lower than the reference group,the differences were statistically significant(P<0.05).After treatment,the serum alanine aminotransferase(ALT),total bilirubin(TBIL)and liver hardness of two groups were lower than those before treatment,and those in the combined group were lower than those in the reference group,the albumin(ALB)of two groups were higher than those before treatment,and that in the combined group was higher than that in the reference group,the differences were statistically significant(P<0.05).After treatment,the prothrombin time(PT)and prothrombin activity(PTA)of two groups were improved compared with those before treatment,and the PT of the combined group was shorter than that of the reference group,and the PTA was higher than that of the reference group,the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between two groups during treatment(P>0.05).Conclusion:Compound Glycyrrhizin combined with Entecavir is significantly effective in the treatment of patients with hepatitis B cirrhosis,it can reduce the degree of liver fibrosis,improve coagulation function and liver function,and without increasing the incidence of adverse reactions.
Compound GlycyrrhizinEntecavirHepatitis B cirrhosisLiver functionCoagulation function
国家科技期刊平台
NSTL
万方数据
